The recently reported DETECT study that randomized 105 patients with HER2-negative metastatic BC and HER2-positive CTCs between standard chemotherapy with or without lapatinib showed promising preliminary results of improved OS with the addition of lapatinib. Here, ERBB2 is linked to breast cancer.